• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

ONARTUZUMAB Drug Record

  • Summary
  • Interactions
  • Claims
  • ONARTUZUMAB chembl:CHEMBL1743051 Antineoplastic

    Alternate Names:

    METMAB
    METMA-B
    PRO-143996
    RO-5490258
    ONARTUZUMAB
    RO5490258
    PRO-143966

    Drug Info:

    Pharmaceutical Developer Genentech
    Source Reported Drug Name(s) Onartuzumab
    Drug Class MET Inhibitor
    FDA Approval not approved
    Drug Class monoclonal antibody
    Drug Indications antineoplastic agent
    Drug Class Therapeutic Antibodies
    (4 More Sources)

    Publications:

    Shah et al., 2017, Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial., JAMA Oncol
    Spigel et al., 2013, Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer., J. Clin. Oncol.
    Merchant et al., 2013, Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent., Proc. Natl. Acad. Sci. U.S.A.
    Catenacci et al., 2011, Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence., Cancer Discov
  • ONARTUZUMAB   MET

    Interaction Score: 3.24

    Interaction Types & Directionality:
    antibody (inhibitory)
    antagonist (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Indication/Tumor Type esophagus adenocarcinoma
    Indication/Tumor Type gastroesophageal junction adenocarcinoma
    Response Type no benefit

    PMIDs:
    27918764 24101053 23882082 22389872


    Sources:
    TALC MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions CIViC CancerCommons

  • ONARTUZUMAB   ERBB2

    Interaction Score: 0.42

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Onartuzumab + mFOLFOX6
    Indication/Tumor Type gastric adenocarcinoma
    Response Type no benefit

    PMIDs:
    27918764


    Sources:
    JAX-CKB

  • CancerCommons: ONARTUZUMAB

    • Version: 25-July-2013

    Alternate Names:
    Onartuzumab Drug Trade Name
    Onartuzumab Drug Development Name

    Drug Info:
    Drug Class MET Inhibitor
    Source Reported Drug Name(s) Onartuzumab
    Pharmaceutical Developer Genentech

    Publications:

  • MyCancerGenome: ONARTUZUMAB

    • Version: 20-Jun-2017

    Alternate Names:
    METMAB Development Name
    R05490258 Development Name
    OA-5D Development Name

    Drug Info:
    Drug Class Therapeutic Antibodies

    Publications:

  • TdgClinicalTrial: METMAB

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antineoplastic agent
    Drug Class monoclonal antibody
    FDA Approval not approved

    Publications:

  • JAX-CKB: Onartuzumab

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Shah et al., 2017, Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial., JAMA Oncol
    Spigel et al., 2013, Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer., J. Clin. Oncol.
    Merchant et al., 2013, Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent., Proc. Natl. Acad. Sci. U.S.A.

  • CIViC: ONARTUZUMAB

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    Catenacci et al., 2011, Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence., Cancer Discov

  • TALC: ONARTUZUMAB

    • Version: 12-May-2016

    Alternate Names:
    ONARTUZUMAB Primary Drug Name
    ONARTUZUMAB Drug Generic Name
    METMAB Drug Synonym

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1743051

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL1743051

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21